Claims
- 1. A method for enhancing memory consolidation in an animal, comprising administering to the animal a formulation of a methylphenidate compound, or pharmaceutically acceptable derivative, salt, solvate, pro-drug or metabolic derivative thereof, in an amount sufficient to enhance long-term memory in the animal.
- 2. The method of claim 1, wherein the methylphenidate compound is represented by the general formula (I):
- 3. The method of claim 1, wherein the methylphenidate compound is represented by the general formula (II), or pharmaceutically acceptable salt, pro-drug or metabolic derivative thereof:
- 4. The method of claim 1, wherein the pharmaceutically acceptable salt of methylphenidate compound is represented by the general formula (III):
- 5. The method of claim 1, wherein the pharmaceutically acceptable salt of methylphenidate compound is represented by the general formula (IV), or a pharmaceutically acceptable salt, solvate or pro-drug thereof:
- 6. The method of claim 1, wherein the metabolite of methylphenidate compound is represented by the general formula (V), or a pharmaceutically acceptable salt, solvate or pro-drug thereof:
- 7. The method of claim 2, wherein R2 represents H or C1-C6 alkyl.
- 8. The method of claim 2, wherein U represents —C(═O)— or —C(═S)—.
- 9. The method of claim 2, wherein at least one occurrence of V is present.
- 10. The method of claim 9, wherein V is absent for one occurrence, and in the other V represents NH, S, or O.
- 11. The method of claim 2, wherein A represents an aryl or heteroaryl ring.
- 12. The method of claim 2, wherein the ratio DL-erythro stereoisomers to DL-threo stereoisomers is in the range of 1:4 to 1:1.
- 13. The method of claim 2, wherein the formulation is substantially free of erythro stereoisomers.
- 14. The method of claim 2, wherein the formulation is provided as a transdermal patch.
- 15. A transdermal patch for enhancing memory in an animal, comprising methylphenidate, or an analog thereof, in an amount sufficient to enhance long-term memory in an animal.
- 16. The transdermal patch of claim 15, wherein the methylphenidate compound is represented in the general formula (II), or pharmaceutically acceptable salt, pro-drug or metabolic derivative thereof:
- 17. The transdermal patch of claim 16, wherein the ratio D-threo stereoisomer to L-threo stereoisomer is in the range of 1:4 to 1:1.
- 18. The transdermal patch of claim 16, wherein the formulation is substantially free of erythro stereoisomers.
- 19. The transdermal patch of claim 15, further comprising one or more penetration enhancers.
RELATED APPLICATIONS
[0001] This is a continuation of International Application No. PCT/US01/26829, which designated the United States, was published in English, and was filed on Aug. 28, 2001. This application also claims the benefit of U.S. Provisional Application Nos. 60/228,525, filed on Aug. 28, 2000, 60/235,971, filed on Sep. 28, 2000, and 60/248,278, filed on Nov. 14, 2000. The teachings of the above applications are incorporated herein by reference in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60228525 |
Aug 2000 |
US |
|
60235971 |
Sep 2000 |
US |
|
60248278 |
Nov 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/26829 |
Aug 2001 |
US |
Child |
10374732 |
Feb 2003 |
US |